Virtual Library

Start Your Search

Caroline Lee



Author of

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-25 - TOURIST: Thoracic Umbrella Radiotherapy Study in Stage IV NSCLC: A Phase III Randomized Trial in Development (Now Available) (ID 1024)

      10:15 - 18:15  |  Author(s): Caroline Lee

      • Abstract
      • Slides

      Background

      Non Small Cell Lung Cancer (NSCLC) is the leading cause of cancer mortality throughout the world with an incidence exceeding 1.2 million. 70% of NSCLC patients present with incurable disease with treatment aimed at alleviating symptoms, maintaining / improving quality of life as well as prolonging survival.

      In the last decade there have been dramatic changes in systemic therapy (chemotherapy, immunotherapy, Tyrosine kinase Inhibitors (TKIs)). Despite these advances, many patients suffer from lororegional symptomatic relapse. This may benefit from local radiotherapy in addition to other standards of care such as symptom control. Radiotherapy remains widely used in the management of stage IV NSCLC but strategies vary hugely because the data originates from a series of dose fractionations trials in the 1990s when systemic therapy options were limited.

      There is therefore limited evidence regarding the use and place of palliative radiotherapy in conjunction with modern systemic treatments and there is a need to assess benefits of advanced radiotherapy techniques in this population. The TOURIST trial aims to establish the utility of palliative thoracic radiotherapy in the primary treatment of stage IV NSCLC.

      Method

      This is a phase III platform that currently has 2 study arms, to cover the needs of differing patient populations, defined by the use of first line systemic therapy.

      Study 1 (PRINCE) Patients receiving first line systemic therapy as standard of care, who have not progressed after 2-4 cycles are randomised 1:1 to either high dose palliative radiotherapy to the thorax, or to no radiotherapy while continuing on their standard systemic therapy. Co-primary endpoints: overall survival, PROMs recorded QOL, with progression free survival and time to next line of therapy, as secondary endpoints.

      Study 2 (QUARTZ Lung) Asymptomatic patients unsuitable for standard systemic therapy randomised 1:1 to low dose palliative radiotherapy dose to the thorax or no radiotherapy. Telephone follow up will be used for PROMs data collection to measure QOL improvements.

      Stratification factors for both studies will include bulk of thoracic disease, use of advanced radiotherapy techniques and performance status. The TOURIST trial intends to recruit 750 patients and is anticipated to open in 2020.

      Result

      Section not applicable

      Conclusion

      Section not applicable

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.